Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · Real-Time Price · USD
6.30
-0.16 (-2.48%)
May 15, 2026, 11:27 AM EDT - Market open
Ardelyx Revenue
Ardelyx had revenue of $94.47M in the quarter ending March 31, 2026, with 27.47% growth. This brings the company's revenue in the last twelve months to $427.68M, up 18.24% year-over-year. In the year 2025, Ardelyx had annual revenue of $407.32M with 22.09% growth.
Revenue (ttm)
$427.68M
Revenue Growth
+18.24%
P/S Ratio
3.73
Revenue / Employee
$874,599
Employees
489
Market Cap
1.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 407.32M | 73.71M | 22.09% |
| Dec 31, 2024 | 333.62M | 209.16M | 168.06% |
| Dec 31, 2023 | 124.46M | 72.30M | 138.61% |
| Dec 31, 2022 | 52.16M | 42.06M | 416.57% |
| Dec 31, 2021 | 10.10M | 2.53M | 33.36% |
| Dec 31, 2020 | 7.57M | 2.29M | 43.36% |
| Dec 31, 2019 | 5.28M | 2.67M | 102.57% |
| Dec 31, 2018 | 2.61M | -39.39M | -93.79% |
| Dec 31, 2017 | 42.00M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 24.03M | -7.60M | -24.02% |
| Dec 31, 2014 | 31.62M | 2.70M | 9.32% |
| Dec 31, 2013 | 28.93M | 23.52M | 434.71% |
| Dec 31, 2012 | 5.41M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novavax | 596.34M |
| Innoviva | 420.69M |
| Vericel | 292.09M |
| Iovance Biotherapeutics | 285.61M |
| Nuvation Bio | 143.05M |
| Nurix Therapeutics | 71.78M |
| Recursion Pharmaceuticals | 66.41M |
| Agios Pharmaceuticals | 66.05M |
ARDX News
- 8 days ago - Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF's Spring Clinical Meetings - GlobeNewsWire
- 14 days ago - Ardelyx reports Q1 EPS (15c), consensus (14c) - TheFly
- 14 days ago - Ardelyx Earnings Call Transcript: Q1 2026 - Transcripts
- 14 days ago - Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 18 days ago - Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF's Spring Clinical Meetings - GlobeNewsWire
- 22 days ago - Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026 - GlobeNewsWire
- 23 days ago - Jade Biosciences appoints Edward Conner as chief medical officer - TheFly
- 25 days ago - Ardelyx appoints Ettenberg as Chief Legal Officer - TheFly